Pablo Legorreta

Pablo Legorreta

Chief Executive OfficeratRoyalty Pharma· In proxies 2023–2025

Pay in FY2025Royalty Pharma stock +51.5% the same year

Pablo Legorreta was paid $937.5K in FY2025 (Dec). Royalty Pharma stock rose 51.5% that year.

Pay$100 in the stock at the end of FY24 → $151
Pay is from the Summary Compensation Table of each Royalty Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Royalty PharmaPublic company · 3 yr
    • Chief Executive Officer2023 – Present · 3 yrStock in role +65%
  2. ProKidney CoPublic company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Boards1

  • Royalty PharmaChair · 5 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?